Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Apr;39(4):452–455. doi: 10.1111/j.1365-2125.1995.tb04477.x

Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.

S A Corlett 1, D Parker 1, H Chrystyn 1
PMCID: PMC1365136  PMID: 7640155

Abstract

Ifosfamide is a chiral pro-drug which is administered clinically in its racemic form. Serum concentrations of rac-ifosfamide and its enantiomers were measured in 12 patients with lung carcinoma following a mean (+/- s.d.) intravenous dose of 4.2 (0.83) g infused over 1 h. The mean (+/- s.d.) volumes of distribution (VSS) of rac, (R)- and (S)-ifosfamide were 0.61 (0.17), 0.60 (0.16) and 0.61 (0.19) l kg-1, respectively. The mean (+/- s.d.) half-lives and clearances were 6.57 (1.69), 7.12 (1.92) and 5.98 (1.52) h and 0.065 (0.013), 0.060 (0.013) and 0.072 (0.014) l h-1 kg-1 for rac, (R)- and (S)-ifosfamide, respectively. The half-life of (S)-ifosfamide was significantly (P < 0.001) shorter than that of (R)-ifosfamide and it had a significantly higher clearance (P < 0.001). There was no significant difference in the volumes of distribution of the enantiomers. The clinical significance of the faster elimination of (S)-ifosfamide is not known.

Full text

PDF
452

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. M., Creaven P. J. Pharmacokinetics of ifosfamide. Clin Pharmacol Ther. 1975 Apr;17(4):492–498. doi: 10.1002/cpt1975174492. [DOI] [PubMed] [Google Scholar]
  2. Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug;68(8):1071–1074. doi: 10.1002/jps.2600680845. [DOI] [PubMed] [Google Scholar]
  3. Boddy A. V., Yule S. M., Wyllie R., Price L., Pearson A. D., Idle J. R. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res. 1993 Aug 15;53(16):3758–3764. [PubMed] [Google Scholar]
  4. Boos J., Welslau U., Ritter J., Blaschke G., Schellong G. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol. 1991;28(6):455–460. doi: 10.1007/BF00685822. [DOI] [PubMed] [Google Scholar]
  5. Cerny T., Castiglione M., Brunner K., Küpfer A., Martinelli G., Lind M. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet. 1990 Jan 20;335(8682):175–175. doi: 10.1016/0140-6736(90)90053-8. [DOI] [PubMed] [Google Scholar]
  6. Corlett S. A., Chrystyn H. Enantiomeric separation of R- and S-ifosfamide and their determination in serum from clinical subjects. J Chromatogr B Biomed Appl. 1994 Mar 18;654(1):152–158. doi: 10.1016/0378-4347(93)e0446-w. [DOI] [PubMed] [Google Scholar]
  7. Costanzi J. J., Gagliano R., Loukas D., Panettiere F. J., Hokanson J. A. Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. Cancer. 1978 May;41(5):1715–1719. doi: 10.1002/1097-0142(197805)41:5<1715::aid-cncr2820410510>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  8. Lewis L. D., Fitzgerald D. L., Harper P. G., Rogers H. J. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol. 1990 Nov;30(5):725–732. doi: 10.1111/j.1365-2125.1990.tb03842.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lewis L. D., Fitzgerald D. L., Mohan P., Thatcher N., Harper P. G., Rogers H. J. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol. 1991 Jan;31(1):77–82. doi: 10.1111/j.1365-2125.1991.tb03860.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lewis L. D., Fitzgerald D. L., Mohan P., Thatcher N., Harper P. G., Rogers H. J. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol. 1991 Jan;31(1):77–82. doi: 10.1111/j.1365-2125.1991.tb03860.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lewis L. D. Ifosfamide pharmacokinetics. Invest New Drugs. 1991 Nov;9(4):305–311. doi: 10.1007/BF00183570. [DOI] [PubMed] [Google Scholar]
  12. Lind M. J., Margison J. M., Cerny T., Thatcher N., Wilkinson P. M. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res. 1989 Feb 1;49(3):753–757. [PubMed] [Google Scholar]
  13. Lind M. J., Margison J. M., Cerny T., Thatcher N., Wilkinson P. M. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol. 1989;25(2):139–142. doi: 10.1007/BF00692355. [DOI] [PubMed] [Google Scholar]
  14. Lind M. J., Margison J. M., Cerny T., Thatcher N., Wilkinson P. M. The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol. 1990 Jul;30(1):140–143. doi: 10.1111/j.1365-2125.1990.tb03754.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Paprocka M., Kuśnierczyk H., Budzyński W., Rak J., Radzikowski C. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers. Arch Immunol Ther Exp (Warsz) 1986;34(3):275–284. [PubMed] [Google Scholar]
  16. Prasad V. K., Corlett S. A., Abaasi K., Heney D., Lewis I., Chrystyn H. Ifosfamide enantiomers: pharmacokinetics in children. Cancer Chemother Pharmacol. 1994;34(5):447–449. doi: 10.1007/BF00685573. [DOI] [PubMed] [Google Scholar]
  17. Rodriguez V., Bodey G. P., Freireich E. J., McCredie K. B., McKelvey E. M., Tashima C. K. Reduction of ifosfamide toxicity using dose fractionation. Cancer Res. 1976 Aug;36(8):2945–2948. [PubMed] [Google Scholar]
  18. Walker D., Flinois J. P., Monkman S. C., Beloc C., Boddy A. V., Cholerton S., Daly A. K., Lind M. J., Pearson A. D., Beaune P. H. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol. 1994 Mar 29;47(7):1157–1163. doi: 10.1016/0006-2952(94)90387-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES